natgillin/translations-raw huggingface dataset:
Vildagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. 
Zmanjšuje tudi tvorbo glukoze v jetrih, in sicer z zviševanjem koncentracije insulina in zniževanjem koncentracije hormona glukagona.
In contrast, patients adding placebo to their existing treatment showed smaller changes in HbA1c levels, ranging from a fall of 0.3 to a rise of 0.2 percentage points. 
Nasprotno pa je bila pri bolnikih, ki so poleg obstoječega zdravljenja prejemali placebo, sprememba koncentracije HbA1c manjša in je znašala od znižanja za 0,3 odstotne točke do povečanja za 0,2 odstotne točke.
In combination with metformin and glimepiride, 50 mg Galvus taken twice a day reduced HbA1c levels by 1 percentage point, compared with a reduction of 0.3 percentage points in patients taking placebo. 
V kombinaciji z metforminom in glimepiridom je zdravilo Xiliarx v odmerku 50 mg dvakrat na dan znižalo ravni HbA1c za eno odstotno točko v primerjavi z znižanjem za 0,3 odstotne točke pri bolnikih, ki so jemali placebo.
Patients taking Galvus in addition to insulin, with or without metformin, had a reduction in HbA1c levels of 0.77 percentage points, compared with 0.05 percentage points in patients taking placebo in addition to insulin. 
Pri bolnikih, ki so zdravilo Xiliarx jemali kot dodatek insulinu z metforminom ali brez njega, se je raven HbA1c znižala za 0,77 odstotne točke, medtem ko se je pri bolnikih, ki so kot dodatek insulinu jemali placebo, znižala le za 0,05 odstotne točke.
• together with a sulphonylurea and metformin (triple therapy) in patients whose diabetes is not sufficiently controlled by these medicines plus diet and exercise; 
• skupaj s sulfonilsečnino in metforminom (zdravljenje s tremi zdravili) pri bolnikih, pri katerih sladkorna bolezen ni zadostno urejena s temi zdravili, dieto in telesno vadbo;
• together with insulin (with or without metformin) in patients whose diabetes is not sufficiently controlled by diet and exercise plus a stable dose of insulin. 
• skupaj z insulinom (z metforminom ali brez njega) pri bolnikih, pri katerih sladkorna bolezen ni zadostno urejena z dieto in telesno vadbo ter ustaljenim odmerkom insulina.
Five of these studies looked at the effects of Xiliarx taken alone in a total of 3,644 patients, comparing it with placebo (a dummy treatment), metformin, rosiglitazone (a thiazolidinedione) or gliclazide (a sulphonylurea). 
V petih študijah so pri skupno 3 644 bolnikih proučevali učinke zdravila Xiliarx, uporabljenega samostojno, ter jih primerjali z učinki placeba (zdravila brez zdravilne učinkovine), metformina, rosiglitazona (tiazolidindiona) ali gliklazida (sulfonilsečnine).
With metformin and with pioglitazone, the 100 mg daily dose was more effective than the 50 mg daily dose, with a reduction in HbA1c levels of between 0.8 and 1.0 percentage points. 
Pri njegovi uporabi z metforminom in pioglitazonom je bil 100-miligramski dnevni odmerek učinkovitejši od 50-miligramskega, pri čemer se je koncentracija HbA1c znižala za 0,8 do 1,0 odstotne točke.
• on its own (monotherapy) in patients whose diabetes is not sufficiently controlled by diet and exercise and who cannot take metformin; 
• samostojno (zdravljenje z enim zdravilom) pri bolnikih, pri katerih sladkorna bolezen ni zadostno urejena s prehrano in telesno vadbo ter ki ne morejo jemati metformina;
How has Xiliarx been studied? 
Kako je bilo zdravilo Xiliarx raziskano?
What is Xiliarx used for? 
Za kaj se zdravilo Xiliarx uporablja?
What is Xiliarx? 
Kaj je zdravilo Xiliarx?
How does Xiliarx work? 
Kako zdravilo Xiliarx deluje?
A further study compared Galvus with placebo as an add-on treatment in 318 patients who were already taking metformin and glimepiride. 
V nadaljnji študiji so pri 318 bolnikih, ki so že jemali metformin ali glimepirid, zdravilo Xiliarx primerjali s placebom, kadar sta bila uporabljena kot dodatek zdravljenju.
How is Xiliarx used? 
Kako se zdravilo Xiliarx uporablja?
A further study compared Galvus with placebo as an add-on treatment in 449 patients who were already taking a stable dose of long-acting insulin. 
V nadaljnji študiji so pri 449 bolnikih, ki so že jemali ustaljen odmerek insulina z dolgotrajnim delovanjem, zdravilo Xiliarx primerjali s placebom, kadar sta bila uporabljena kot dodatek zdravljenju.
This medicine is the same as Galvus, which is already authorised in the European Union (EU). 
Ta odobritev je temeljila na dovoljenju za promet, odobrenemu za zdravilo Galvus leta 2007 (uporaba dokumentacije s soglasjem).
The physician information should contain the following key messages: 
Informacije za zdravnika morajo vsebovati naslednje pomembne informacije:
• The need to evaluate patients for both active and inactive tuberculosis prior to starting the treatment, including use of appropriate screening tests, 
• Potreba po testiranju bolnikov za aktivno in neaktivno tuberkulozo pred zdravljenjem, vključno z uporabo ustreznih presejalnih testov.
• The role and use of patient alert card. 
• Uporaba in namen bolnikove opozorilne kartice.
• Physician information 
• Informacije za zdravnika
The Member States should ensure that all conditions or restrictions with regard to the safe and effective use of the medicinal product described below are implemented: 
Države članice morajo izpolniti vse pogoje za zagotovitev varnosti in učinkovitosti uporabe zdravila, ki so opisani spodaj:
• Patient Alert Card 
• Bolnikovo opozorilno kartico
• The risk of serious infections, including opportunistic bacterial, viral and fungal infections in patients treated with Simponi, 
• Možnost za tveganje hudih okužb vključno z oportunističnimi bakterijami, virusnimi okužbami in glivičnimi okužbami pri bolnikih, ki prejemajo zdravilo Simponi.
• The contraindication of Simponi in patients with history of moderate to severe heart failure (NYHA III/IV), and potential risk of congestive heart failure being worsened by Simponi, 
• Kontraindicirano zdravljenje za bolnike s preteklo zmerno do hudo boleznijo srca (NYHA III/IV) in z možnostjo tveganja za poslabšanje kongestivne srčne bolezni po zdravljenju z zdravilom Simponi.
The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are expected to prescribe/use Simponi are provided with a physician information pack containing the following: 
Imetnik dovoljenja za promet z zdravilom mora pred prihodom zdravila na trg zagotoviti, da bodo vsi možni predpisovalci zdravila prejeli informacije namenjene zdravnikom, ki bodo vsebovale:
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
POGOJI ALI OMEJITVE GLEDE VARNOSTI IN ČINKOVITOSTI UPORABE ZDRAVILA, KI JIH MORAJO IZPOLNITI DRŽAVE ČLANICE
ANNEX CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
DODATEK POGOJI ALI OMEJITVE GLEDE VARNOSTI IN ČINKOVITOSTI UPORABE ZDRAVILA, KI JIH MORAJO IZPOLNITI DRŽAVE ČLANICE
• The risk of acute injection-related reactions and delayed serious systemic hypersensitivity reactions, the need for instructing patients on techniques for administration, and guidance for Health Care Professionals on how to report administration errors, 
Potrebo po informiranju bolnika o tehniki dajanja zdravila in izobraževanu bolniškeg osebja kako poročati o napakah pri dajanju zdravila.
The MAH should submit appropriate scientific evidence to demonstrate a positive benefit-risk balance of the medicinal product in any indication. 
Imetnik dovoljenja za promet z zdravilom mora predložiti ustrezne znanstvene dokaze, ki bodo pokazali pozitivno razmerje med tveganji in koristmi uporabe zdravila pri kateri koli indikaciji.
For the suspension of medicinal products containing nalidixic acid, flumequine, pipemidic acid and cinoxacin to be lifted, the competent authorities shall ensure that the below conditions have been completed by the marketing authorisation holders 
Za preklic začasnega umika dovoljenj za promet z zdravili, ki vsebujejo nalidiksno kislino, flumekvin, pipemidno kislino in cinoksacin, morajo pristojni organi zagotoviti, da so imetniki dovoljenj za promet z zdravilom izpolnili spodnje pogoje.
Annex IV Conditions for lifting the suspension of the marketing authorisations 
Pogoji za preklic začasnega umika dovoljenj za promet z zdravilom
{Name and address} {Tel} {fax} {e-mail} 
{Ime in naslov} {tel.} {faks} {e-pošta}
This is so the doctor knows what you have taken. 
Tako bo zdravnik lahko vedel, kaj ste vzeli.
If this happens, do not drive or use any tools or machines. 
Če se vam to zgodi, ne vozite in ne uporabljajte orodij oziroma strojev.
1000 Ljubljana Slovenia 
1000 Ljubljana Slovenija
This leaflet does not contain all the information about your medicine. 
To navodilo ne vsebuje vseh informacij o vašem zdravilu.
They are used together when treatment with just one did not work. 
Skupaj se uporabljata, če zdravljenje z eno samo od njiju ni učinkovito.
(Invented) name 
Izmišljeno ime
The patient should be closely monitored and the treatment should be symptomatic and supportive. 
Bolnika je treba natančno nadzirati; zdravljenje mora biti simptomatsko in podporno.
This is because the drug has never been used in these age groups. 
Zdravilo namreč v teh starostnih skupinah še ni bilo nikoli uporabljeno.
This could be Raynaud's phenomenon 
To je lahko Raynaudov pojav.
Not known 
Ni znano
• Ringing in your ears 
• zvonjenje v ušesih
2740-244 Porto Salvo Portugal 
2740-244 Porto Salvo Portugalska
However, the effect of multiple doses is not known. 
Toda učinek večkratnih odmerkov ni znan.
This can happen especially at the start of treatment, or when changing over from other preparations. 
To se lahko zgodi zlasti na začetku zdravljenja ali po prehodu z drugih zdravil.
Empreendimento Lagoas Park, Edifício 7 - 3º Piso 
Empreendimento Lagoas Park, Edifício 7 - 3ş Piso
• Reduced sexual desire in men or women 
• zmanjšano spolno poželenje pri moških ali ženskah
• If you have ever had a serious allergic reaction called “angioedema”. 
• če ste kdaj imeli resno alergijsko reakcijo, imenovano "angioedem”.
It may harm them even if their symptoms are the same as yours. 
Njim bi lahko celo škodovalo, čeprav imajo znake bolezni, podobne vašim.
176-74 Kallithea Greece 
176-74 Kallithea Grčija
Critical Evaluation 
Kritično vrednotenje
This medicinal product is authorised in the Member States of the EEA under the following names: 
To zdravilo je odobreno v državah članicah EGP pod naslednjimi imeni: Avstrija:
• Sleep problems 
• težave s spanjem
The elimination half-life is 5 to 6 hours. 
Eliminacijski razpolovni čas je od 5 do 6 ur.
TRITAZIDE is not recommended for children and young people under the age of 18 years. 
Zdravilo TRITAZIDE ni priporočljivo za otroke in mladostnike, mlajše od 18 let.
This change of the text is to ensure it doesn't suggest an immediate artificial abortion, which is not justified by the clinical experiences collected till now. 
Namen te spremembe je zagotoviti, da v besedilu ne bi bil predlagan takojšen umetni splav, saj to ni utemeljeno z dosedanjimi kliničnimi izkušnjami.
This may be a sign of your body holding onto more water than usual 
To je lahko znak, da se v telesu zadržuje več vode kot po navadi
This may be given for an operation or any dental work. 
Dobite ga lahko za operacijo ali kakšen zobozdravstven poseg.
• If you miss a dose, take your normal dose when it is next due. 
• Če ste pozabili vzeti odmerek, vzemite običajen odmerek, ko je čas za naslednjega.
Sulphonamide diuretics should be taken at least one hour before or four to six hours after these medications. 
Sulfonamidne diuretike je treba vzeti vsaj eno uro pred temi zdravili ali od štiri do šest ur po teh zdravilih.
Adverse reactions frequency is defined using the following convention: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data). 
Neželeni učinki so opredeljeni po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), ni znano (ni mogoče oceniti na podlagi podatkov, ki so na voljo).
167 14 Bromma Sweden 
167 14 Bromma Švedska
In most cases the initial dose is the same, but there are differences with respect to subsequent titration (both in terms of frequency of increase and maximum daily dose). 
V večini primerov je začetni odmerek enak, razlike so pri nadaljnjem titriranju (pri pogostosti povečevanja odmerka in največjem dnevnem odmerku).
The list of products which interact or may interact with Tritazide is acceptable. 
Seznam zdravil, ki medsebojno delujejo ali lahko medsebojno delujejo z zdravilom Tritazide, je sprejemljiv.
Elderly Your doctor will reduce the initial dose and adjust your treatment more slowly. 
Starejši Zdravnik bo zmanjšal začetni odmerek in bo bolj počasi prilagajal vaše zdravljenje.
A-1037 Wien 
A-1037 Dunaj
• Sexual inability in men 
• spolna nezmožnost pri moških
It is recommended to monitor the white blood cell count to permit detection of a possible leucopoenia. 
Priporočljivo je kontrolirati belo krvno sliko, da bi odkrili morebitno levkopenijo.
Tritazide was included in the list of products for Summary of Products Characteristics (SPC) harmonisation, drawn up by the CMD(h), in accordance with Article 30(2) of Directive 2001/83/EC, as amended, as the abovementioned medicinal product does not have the same SPC across EU Member States, Iceland and Norway. 
Zdravilo Tritazide je bilo vključeno na seznam zdravil za uskladitev povzetka glavnih značilnosti zdravila (SPC), ki ga je pripravil CMD(h), v skladu s členom 30(2) Direktive 2001/83/ES, kakor je bila spremenjena, saj zgoraj navedeno zdravilo nima enakega povzetka glavnih značilnosti zdravila v državah članicah EU, na Islandiji in Norveškem.
Patient should be kept under observation for at least 12 to 24 hours and discharged after complete resolution of the symptoms. 
Bolnika je treba opazovati vsaj 12 do 24 ur in ga odpustiti šele po popolnem izginotju simptomov.
POLIFARMA SPA Viale dell'Arte 69 00144 Roma Italy 
POLIFARMA SPA Viale dell'Arte 69 00144 Rim Italija
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF TRITAZIDE AND ASSOCIATED NAMES (SEE ANNEX I) 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA TRITAZIDE IN Z NJIM POVEZANIH IMEN (GLEJTE DODATEK I)
• Severe stomach pain which may reach through to your back. 
• huda bolečina v želodcu, ki lahko sega v hrbet.
Initial doses should be lower and subsequent dose titration should be more gradual because of greater chance of undesirable effects especially in very old and frail patients. 
Začetni odmerek mora biti manjši, nadaljnja titracija pa bolj postopna, ker obstaja večja možnost neželenih učinkov, zlasti pri zelo starih in slabotnih bolnikih.
Emergency therapy should be instituted promptly. 
Nemudoma je treba uvesti nujno zdravljenje.
Zentiva HU Kft Népfürdo u.22 1138 Budapest Hungary 
Zentiva HU Kft Népfürdo u.22 1138 Budapest Madžarska
Testing should be more frequent in elderly and cirrhotic patients. 
Kontrole morajo biti pogostejše pri starejših bolnikih in bolnikih s cirozo.
The combination product can be considered as bioequivalent to products containing the individual components. 
Kombinirano zdravilo lahko obravnavamo kot bioekvivalentno zdraviloma, ki vsebujeta posamezni sestavini.
• Change in the way things smell 
• spremembe vonja stvari
Taking TRITAZIDE with food and alcohol 
Jemanje zdravila TRITAZIDE s hrano in alkoholom
TRITAZIDE can be taken before, with or after meals, because food intake does not modify its bioavailability (see section 5.2). 
TRITAZIDE je mogoče vzeti pred obroki, med njimi ali po njih, ker uživanje hrane ne vpliva na biološko uporabnost (glejte poglavje 5.2).
• TRITAZIDE may be taken with or without food. 
• Zdravilo TRITAZIDE lahko vzamete s hrano ali brez nje.
- the Summaries of Products Characteristic, labelling and package leaflet proposed by the Marketing Authorisation Holders has been assessed based on the documentation submitted and the scientific discussion within the Committee, 
- so bili povzetek glavnih značilnosti zdravila, označevanje in navodilo za uporabo, ki so jih predlagali imetniki dovoljenja za promet z zdravilom, ocenjeni na podlagi predložene dokumentacije in znanstvene razprave znotraj Odbora,
• Shortness of breath, cough fever lasting 2 to 3 days and feeling less hungry. 
• kratka sapa, kašelj, ki traja od 2 do 3 dni, in občutek manjše lakote.
• If you are going to receive an anaesthestic. 
• če boste dobili anestetik.
• Primary Hyperaldosteronism 
• Primarni hiperaldosteronizem
WHAT TRITAZIDE IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO TRITAZIDE IN ZA KAJ GA UPORABLJAMO
• Making it easier for your heart to pump blood around your body. 
• srcu olajša črpanje krvi po telesu.
This could be a sign of a severe allergic reaction to TRITAZIDE 
To je lahko znak hude alergijske reakcije na zdravilo TRITAZIDE.
AstraZeneca S.p.A Palazzo Volta Via Francesco Sforza 20080 Basiglio (MI) Italy 
AstraZeneca S.p.A Palazzo Volta Via Francesco Sforza 20080 Basiglio (MI) Italija
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription (including herbal medicines). 
Obvestite svojega zdravnika ali farmacevta, če jemljete ali ste pred kratkim jemali katerokoli zdravilo, tudi če ste ga dobili brez recepta, vključno z zeliščnimi pripravki.
The first measurement of plasma potassium levels should be carried out during the first week following the start of treatment. 
Prvo meritev koncentracije kalija v plazmi je treba opraviti prvi teden po začetku zdravljenja.
• You must tell your doctor if you think that you are (or might become) pregnant. 
• Zdravniku morate povedati, če se vam zdi, da ste noseči (ali bi lahko zanosili).
NL-2800 BD Gouda The Netherlands 
NL-2800 BD Gouda Nizozemska
TRITAZIDE is used to treat high blood pressure. 
Zdravilo TRITAZIDE se uporablja za zdravljenje visokega krvnega tlaka.
It is recommended that TRITAZIDE is taken once daily, at the same time of the day, usually in the morning. 
Zdravilo TRITAZIDE je priporočljivo jemati enkrat na dan, vsak dan ob istem času, po navadi zjutraj.
Tell your doctor immediately if you experience: 
Zdravnika morate nemudoma obvestiti, če se vam pojavijo:
Contra-indicated combinations 
Kontraindicirane kombinacije
After the first dose or subsequent increases in dose it is not advisable to drive or operate machinery for several hours. 
Več ur po prvem odmerku ali poznejših povečanjih odmerka ni priporočljivo, da bolnik vozi ali upravlja s stroji.
They are extended with the contraindications of HCTZ. 
Dopolnjujejo jih kontraindikacije HCTZ.
Electrolyte imbalance 
Neravnovesje elektrolitov
• Slowed or impaired reactions 
• počasno ali prizadeto reagiranje
SANOFI-AVENTIS ESTONIA OÜ Pärnu mnt. 139 E/2 11317 Tallinn Estonia 
SANOFI-AVENTIS ESTONIA OÜ Pärnu mnt. 139 E/2 11317 Talin Estonija
Your doctor will need to check your blood pressure. 
Zdravnik vam bo moral kontrolirati krvni tlak.
• Take this medicine by mouth at the same time of day each day, usually in the morning. 
• Zdravilo zaužijte vsak dan ob istem času, po navadi zjutraj.
Please tell your doctor if you are taking any of the following medicines. 
Zdravnika morate obvestiti, če jemljete katero od naslednjih zdravil.
TRITAZIDE has to be swallowed with liquid. 
TRITAZIDE je treba zaužiti s tekočino.
Characteristically, the cough is nonproductive, persistent and resolves after discontinuation of therapy. 
Značilno je, da je ta kašelj neproduktiven, trdovraten in izgine po prekinitvi terapije.
• Do not take a double dose to make up for a forgotten tablet. 
• Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnjo tableto.
• Difficulty breathing or worsening of asthma 
• težko dihanje ali poslabšanje astme
The combination is indicated for the treatment of hypertension in all Member States where licensed, although it is noted that terms including essential hypertension, arterial hypertension and arterial essential hypertension are used. 
Kombinacija je indicirana za zdravljenje hipertenzije v vseh državah članicah, v katerih je zdravilo odobreno, pri čemer velja opozoriti, da se uporablja tudi za zdravljenje esencialne hipertenzije, arterijske hipertenzije in arterijske esencialne hipertenzije.
Some adverse effects (e.g. symptoms of a reduction in blood pressure such as dizziness) may impair the patient's ability to concentrate and react and, therefore, constitute a risk in situations where these abilities are of particular importance (e.g. operating a vehicle or machinery). 
Nekateri neželeni učinki (npr. nekateri simptomi znižanega krvnega tlaka, kot sta omotica) lahko oslabijo zmožnost koncentracije in reagiranja in so torej nevarni v okoliščinah, v katerih so te zmožnosti posebej pomembne (npr. pri upravljanju vozil ali strojev).
Do not take TRITAZIDE if any of the above apply to you. 
Ne vzemite zdravila TRITAZIDE, če kaj od naštetega velja za vas.
Treatment of high blood pressure Your doctor will adjust the amount you take until your blood pressure is controlled. 
Zdravljenje visokega krvnega tlaka Zdravnik vam bo prilagajal količino zdravila, dokler vaš krvni tlak ne bo urejen.
Reproduction studies in rats and rabbits revealed that the combination is somewhat more toxic than either of the single components but none of the studies revealed a teratogenic effect of the combination. 
Študije vplivov na sposobnost razmnoževanja pri podganah in kuncih so pokazale, da je kombinacija nekoliko bolj toksična kot vsaka sestavina zase, vendar nobena teh študij ni pokazala, da bi imela kombinacija teratogen učinek.
The increased renal excretion of these ions is accompanied by increased urine output (due to osmotic binding of water). 
Povečano ledvično izločanje teh ionov spremlja povečano izločanje urina (zaradi osmotske vezave vode).
Athletes Hydrochlorothiazide may produce a positive analytic result in the anti-doping test. 
Športniki Hidroklorotiazid lahko povzroči pozitiven rezultat analize na protidopinškem testu.
• Sweating more than usual or feeling thirsty 
• močneje znojenje kot po navadi ali občutek žeje
Iceland Ireland sanofi-aventis Ireland Ltd. Citywest Business Campus Dublin 24 
Islandija Irska sanofi-aventis Ireland Ltd. Citywest Business Campus Dublin 24
TRITAZIDE is not recommended for use in children and adolescents below 18 years of age due to insufficient data on safety and efficacy. 
TRITAZIDE ni priporočljivo uporabljati pri otrocih in mladostnikih do 18. leta starosti, ker o njegovi varnosti in učinkovitosti v tej skupini ni dovolj podatkov.
• Carbamazepine (for epilepsy). 
• karbamazepin (za epilepsijo).
• Patients at particular risk of hypotension 
• Bolniki s posebnim tveganjem za hipotenzijo
If such treatment is required, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent. 
Če je takšno zdravljenje potrebno, je treba uporabiti drugačno vrsto dializne membrane ali drugo skupino antihipertenzivov.
Anaphylactic reactions during desensitization 
Anafilaktične reakcije med desenzibilizacijo
These patients presented with abdominal pain (with or without nausea or vomiting). 
Ti bolniki so imeli bolečine v trebuhu (z navzeo in bruhanjem ali brez njiju).
• Decreasing your body's production of substances that raise your blood pressure 
• v telesu zmanjša nastajanje določenih snovi, ki zvišujejo krvni tlak
Repeated doses administration studies performed in rats and monkeys revealed only disturbances in electrolytes balance. 
S Študijami uporabe ponavljajočih se odmerkov pri podganah in opicah so odkrili le motnje v ravnovesju elektrolitov.
• If you are having dialysis or any other type of blood filtration. 
• če se zdravite z dializo ali kakšno drugo vrsto filtracije krvi.
Do not take TRITAZIDE: 
Ne jemljite zdravila TRITAZIDE:
Please tell your doctor if any of the following gets serious or lasts longer than a few days. 
Zdravniku ali farmacevtu morate povedati, če kateri od teh neželenih učinkov postane resen ali traja dlje kot le nekaj dni.